DXS International plc Director/Pdmr Shareholding
24 August 2021 - 9:30PM
UK Regulatory
TIDMDXSP
DXS INTERNATIONAL PLC
Notification of Director / PDMR Dealing
The Board of DXS International plc (the "Company"), the AQSE
Growth Market quoted clinical decision support developer and
supplier of clinical decision support systems has received
notification that on 23 August 2021 Mr Bob Sutcliffe, the Chairman,
purchased 10,156 Ordinary Shares in the Company at a price of 12.8p
per share.
Following the transaction specified above Mr Sutcliffe has a
beneficial holding of 555,538 Ordinary Shares representing 1.15% of
the issued share capital of the Company.
Details of the person discharging managerial responsibilities
1 / person closely associated
--- -----------------------------------------------------------------------
a) Name Robert Sutcliffe
--- ---------------------------------- -----------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------------
a) Position/status Chairman
--- ---------------------------------- -----------------------------------
Initial notification
b) /Amendment Initial
--- ---------------------------------- -----------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------
a) Name DXS INTERNATIONAL PLC
--- ---------------------------------- -----------------------------------
b) LEI 2138001R1KEUWTXEVJ44
--- ---------------------------------- -----------------------------------
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
4 have been conducted
--- -----------------------------------------------------------------------
Description of the financial
instrument, type of
a) instrument Ordinary Shares of 0.33p each
---
Identification code ISIN GB00B2Q6HZ92
b) Nature of the transaction Purchase
--- ---------------------------------- -----------------------------------
c) Price(s) and volume(s)
--- --------------- ---------------
Price(s) Volume(s)
--- --------------- ---------------
12.8p 10,156
------------------------------------------------------ ---------------
d) Aggregated information
---
- Aggregated volume
- Price
e) Date of the transaction 23 August 2021
--- ---------------------------------- -----------------------------------
f) Place of the transaction AQSE
--- ---------------------------------- -----------------------------------
The Directors of DXS International plc accept responsibility for
this announcement
Enquiries:
David Immelman (Chief Executive) 01252 719800
DXS International plc david@dxs-systems.com
Wrecclesham House
Wrecclesham Road
Farnham
Surrey
GU10 4PS
www.dxs-systems.co.uk
Corporate Advisor
David Papworth
City & Merchant 0207 101 7676
Corporate Broker
Hybridan LLP
Claire Louise Noyce 020 3764 2341
Note to Editors:
DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other
trusted NHS sources, to doctors, nurses and pharmacists in their
workflow and during the patient consultation. This effective
clinical decision support ultimately translates to improved
healthcare outcomes delivered more cost effectively which should
significantly contribute towards the NHS achieving its projected
efficiency savings.
(END) Dow Jones Newswires
August 24, 2021 07:30 ET (11:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DXS (AQSE:DXSP)
Historical Stock Chart
From Aug 2024 to Sep 2024
DXS (AQSE:DXSP)
Historical Stock Chart
From Sep 2023 to Sep 2024